Daily Archives: March 5, 2015
Bladder cancer mortality was not significantly increased for ventilator users, those with motor incomplete injuries, or those injured less than 10 years.
PURPOSE: To estimate the bladder cancer mortality in persons with spinal cord injury (SCI), as compared to the general population.
MATERIALS AND METHODS: Data and statistics were retrieved from the National SCI Statistical Center and National Center for Health Statistics.
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation’s top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).
The Phase 1/2a trial follows the successful completion of the Phase 1 trial of AST-OPC1, which met its primary endpoints of safety and feasibility when administered to five patients with neurologically complete, thoracic SCI.